Clinical trials: Antibiotics Resistance
MRSA Bloodstream Infection, MRSA Bacteremia
Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia
This is an open-label, expanded access study of exebacase used in addition to antistaphylococcal antibiotics in adult patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)…
- Conditions
- MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
- Trial name
- NCT04597242
- Testing
- Exebacase
- Where
- 2 sites in United States
- Sponsor
- ContraFect
Gram-negative Bacteremia, Microbial Colonization
Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation
ARO-DECAMP is a multi-centre, placebo-controlled, pilot and feasibility randomized controlled trial for the microbial consortium Microbial Ecosystem Therapeutic-2.
- Conditions
- Gram-negative Bacteremia, Microbial Colonization, Antibiotic Resistant Infection
- Trial name
- ARO-DECAMP (NCT06214403)
- Testing
- MET-2
- Where
- 4 sites in Canada
- Sponsor
- University Health Network, Toronto
Intensive Care Unit (ICU) Admission
Biomarker Signature-Supported Antibiotic Treatment Decisions in ICU
The goal of this randomized clinical trial is to determine whether a biomarker-signature (BV) supported antibiotic treatment decision matrix can have a beneficial impact on antibiotic use and patient outcomes in an ICU population.
- Trial name
- BAST-ICU (NCT07481773)
- Testing
- Biomarker-signature supported antibiotic treatment recommendation, Clinical assessment for antibiotic treatment decision
- Where
- 4 sites in Canada
- Volunteers
- 1,200 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Cellulitis of Leg
Cellulitis Optimal Antibiotic Treatment
To determine whether a short course of oral flucloxacillin (5 days) is non-inferior to a standard course (7 days) in terms of pain over days 6-14 (indicative of persistence or recurrence associated with the symptoms of most…
- Trial name
- COAT (NCT05584007)
- Testing
- Flucloxacillin Only Product in Oral Dose Form
- Where
- United Kingdom
- Volunteers
- 334 people
- Sponsor
- University of Southampton
Urinary Tract Infections
Point of Care Susceptibility Testing in Primary Care
The purpose of this study is to determine whether point-of-care susceptibility testing improve correct choice of antibiotics, clinical and microbiological outcome in patients with uncomplicated urinary tract infection in general…
- Trial name
- NCT02323087
- Testing
- FLEXICULT™ SSI-Urinary Kit, ID FlexicultTM
- Where
- Denmark
- Volunteers
- 377 people
- Sponsor
- University of Copenhagen
Gastritis
A Multi-center Study for Eradication of Refractory Helicobacter Pylori
Recently studies showed that the eradication rate of H. pylori fail to exceed 80% and even falls into an unacceptable range. A major cause of treatment failure is associated with antibiotic resistance and poor patient compliance.
- Trial name
- NCT02741414
- Testing
- The result of H pylori culture based on gram staining and enzyme activity testing, The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole, The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing
- Where
- China
- Volunteers
- 4,428 people
- Sponsor
- Taizhou Hospital
Antibiotic-associated Diarrhea
Prevention of Antibiotic-Associated Diarrhoea With Prolardii
Prolardii contains intestinal bacteria, a yeast, a fructo-oligosaccharide and a plant extract that can contribute to the intestinal comfort.
- Trial name
- PAADI (NCT03256708)
- Testing
- Prolardii
- Where
- Belgium
- Volunteers
- 220 people
- Sponsor
- Therabel Pharma SA/NV
Pneumonia, Ventilator-Associated
Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia
The TOP-MDRVAP trial will test whether inhaled tobramycin can safely prevent pneumonia caused by multidrug-resistant bacteria in adults who need a breathing machine. Tobramycin is an antibiotic.
- Trial name
- TOP-MDRVAP (NCT07856355)
- Testing
- Tobramycin inhalation solution
- Where
- China
- Volunteers
- 574 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Antibiotic Selection Pressure
Amplification and Selection of Antimicrobial Resistance in the Intestine II
Stool samples will be collected from two groups of neutropenic patients in the case that a therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected infection.
- Trial name
- ASARI II (NCT03140826)
- Testing
- meropenem
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Helicobacter Pylori Infection
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human gastric mucosa and is associated with chronic gastritis that can progress to severe complications such as peptic ulcer disease, gastric adenocarcinoma and…
- Trial name
- NCT06200779
- Testing
- Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- Where
- Portugal
- Volunteers
- 160 people
- Sponsor
- Manuel Coelho da Rocha
Antimicrobial Stewardship, Drug Resistance, Bacterial
Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo
Emergence of antibiotic resistance (AMR) is a serious concern for Low and Middle Income Countries (LMICs). Unregulated use of antibiotics, a major AMR driver, is highly prevalent in LMICs, with medicine stores as key providers.
- Trial name
- CABU-B/C (NCT05378880)
- Testing
- Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission
- Where
- 2 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 5,532 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Multi-Drug Resistant Organism Colonization
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO).
- Trial name
- NCT06321536
- Testing
- Allogeneic Microbiota in Glycerol (9%) (AMG)
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Gram-Negative Bacterial Infections
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit
Antimicrobial resistance is a global health emergency estimated to be responsible for 700,000 deaths per year worldwide, and it is well known that previous antibiotic exposure is the single most contributing factor.
- Trial name
- RESTART (NCT05171257)
- Testing
- IV antibiotic treatment from prior, differing IV antibiotic treatment
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- Methodist Health System
Antimicrobial Stewardship, Antimicrobial Drug Resistance
Peer Comparison Feedback As An Antimicrobial Prescribing Intervention To General Medicine Specialists
The purpose of this study is to evaluate the effect of a peer comparison feedback report, combined with a best practices toolkit, on the volume of antimicrobial use by general medicine physicians.
- Trial name
- PEER AIMS (NCT07189364)
- Testing
- Peer Comparison Feedback Report
- Where
- Canada
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Fahad Razak
Urinary Tract Infection
Nosocomial Bacteriuria in Geriatric Internal Medicine Services and Follow-up Care and Geriatric Rehabilitation of the Strasbourg University Hospitals
This thesis is a comparative study of the epidemiological characteristics of health-care associated bacteriuria in short and medium term of geriatrics wards in Strasbourg's University Hospital, between 2003 and 2017, in the…
- Trial name
- NCT03577769
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Multidrug-Resistant Organism Infection, Healthcare-Associated Infections (HAIs)
Prevalence of Multidrug-Resistant Organism Infections in General Adult Wards in Argentina (PREV-AR 2 - IGA)
This study measures how common infections caused by multidrug-resistant organisms (MDROs) are among adult patients hospitalized in general medical and surgical wards in Argentina, and how these infections relate to in-hospital…
- Conditions
- Multidrug-Resistant Organism Infection, Healthcare-Associated Infections (HAIs), Antimicrobial Resistance (AMR)
- Trial name
- PREVAR 2-IGA (NCT07797569)
- Testing
- Observational data collection (chart review / point-prevalence survey)
- Where
- Argentina
- Volunteers
- 2,000 people
- Sponsor
- Hospital Italiano de Buenos Aires
Catheter-Related Infections, Biofilms
Biofilm-induced Antimicrobial Resistance RIsk ERadication in Critical Care Central Venous Catheters
Central venous catheter (CVC) infections are a frequent and serious nosocomial complication in critical care, leading to increased morbidity, mortality, and costs.
- Conditions
- Catheter-Related Infections, Biofilms, Infection Prevention
- Trial name
- BARRIER (NCT07546994)
- Testing
- Microbial analysis of catheter biofilm
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection
Optimizing Antibiotic Prescription in STI Clinics Using Rapid POCT
Sexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are increasing in France, with a significant proportion of asymptomatic infections.
- Conditions
- Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Sexually Transmitted Infections, Antimicrobial Resistance / Antibiotic Overuse
- Trial name
- OPTIMISE (NCT07884656)
- Testing
- cobas® Liat® CT/NG Point-of-Care Test
- Where
- 2 sites in France
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Methicillin-Resistant Staphylococcus Aureus, Recurrence
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
The overall goal of the project is to develop and evaluate a home-based intervention to prevent re-infection and transmission of Community-Acquired Methicillin-resistant Staphylococcus aureus (CA-MRSA) in patients presenting to…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
- Trial name
- CAMP-2 (NCT02566928)
- Testing
- 2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol
- Where
- 6 sites in United States
- Volunteers
- 278 people
- Sponsor
- Clinical Directors Network
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento